PredictImmune Gains CE-IVD Mark for IBD Test

Dec 11, 2018

|

NEW YORK (GenomeWeb) – PredictImmune has obtained a CE-IVD mark for its debut test for inflammatory bowel disease, the company said today.

By achieving certification for the test, called PredictSure IBD, the Cambridge, UK-based firm can sell it for clinical use across Europe and other geographies that recognize the designation.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Scan

Back for Another Round

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

Imprints Left Behind

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

Get the Most Out of It

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

Cell Papers Explore Translation, Messenger RNA Localization

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.

Featured White Papers

Epigenomic Analysis of Sorted Retinal Ganglion Cells using ATAC-seq

Cloning Bovine Immunoglobulin VH and VL Genes from Single B Cells

Automated RT qPCR Utilizing the Access Workstation, the Echo Liquid Handler, and RealTime Ready Reagents from Roche Applied Science

High-throughput Miniaturized Quantitative PCR with the Echo 525 Liquid Handler

Jul

24

Featured Webinar

Comparison of Group B Streptococcus Molecular Assays for Routine Screening in Pregnant Women

This webinar will share the results of comparisons of commercially available nucleic acid amplification tests for use in routine screening of pregnant women for Group B Streptococcus (GBS).

Jul

30

Featured Webinar

Single-Cell Sequencing Reveals Clonal Heterogeneity in Acute Lymphoblastic Leukemia

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Jul

31

Featured Webinar

Considerations and Impact of Implementing Targeted NGS in Myeloid Malignancies

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.

Menu